Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 18:10:1547-1571.
doi: 10.2147/JHC.S404424. eCollection 2023.

Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma

Ashraf Omar  1 , Ahmed Kaseb  2 , Tamer Elbaz  1 , Mohamed El-Kassas  3 , Amr El Fouly  3 , Abdel Fatah Hanno  4 , Ahmed El Dorry  5 , Ahmed Hosni  6 , Amr Helmy  7 , Amr S Saad  8 , Ashwaq Alolayan  9 , Basem Elsayed Eysa  10 , Emad Hamada  11 , Hamdy Azim  11 , Hany Khattab  12 , Hesham Elghazaly  8 , Hesham Tawfik  13 , Hisham Ayoub  14 , Hussein Khaled  11 , Ibtessam Saadeldin  11 , Imam Waked  15 , Eman M F Barakat  16 , Mahmoud El Meteini  17 , Mohamed Hamed Shaaban  6 , Mohamed EzzElarab  10 , Mohamed Fathy  17 , Mohamed Shaker  5 , Mohamed Sobhi  5 , Mohamed Kamal Shaker  16 , Mohamed ElGharib  5 , Mohammed Abdullah  11 , Mohesn Mokhtar  11 , Mostafa Elshazli  18 , Omar Mohamed Khaleil Heikal  14 , Osama Hetta  5 , Reda Mahmoud ElWakil  16 , Sameh Abdel Wahab  5 , Samir Shehata Eid  19 , Yousri Rostom  20 ; Egyptian Liver Cancer Committee Study Group
Affiliations
Review

Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma

Ashraf Omar et al. J Hepatocell Carcinoma. .

Erratum in

Abstract

Globally, hepatocellular carcinoma (HCC) is the fourth most common cause of death from cancer. The prevalence of this pathology, which has been on the rise in the last 30 years, has been predicted to continue increasing. HCC is the most common cause of cancer-related morbidity and mortality in Egypt and is also the most common cancer in males. Chronic liver diseases, including chronic hepatitis C, which is a primary health concern in Egypt, are considered major risk factors for HCC. However, HCC surveillance is recommended for patients with chronic hepatitis B virus (HBV) and liver cirrhosis; those above 40 with HBV but without cirrhosis; individuals with hepatitis D co-infection or a family history of HCC; and Nonalcoholic fatty liver disease (NAFLD) patients exhibiting significant fibrosis or cirrhosis. Several international guidelines aid physicians in the management of HCC. However, the availability and cost of diagnostic modalities and treatment options vary from one country to another. Therefore, the current guidelines aim to standardize the management of HCC in Egypt. The recommendations presented in this report represent the current management strategy at HCC treatment centers in Egypt. Recommendations were developed by an expert panel consisting of hepatologists, oncologists, gastroenterologists, surgeons, pathologists, and radiologists working under the umbrella of the Egyptian Society of Liver Cancer. The recommendations, which are based on the currently available local diagnostic aids and treatments in the country, include recommendations for future prospects.

Keywords: Egypt; Egyptian society of liver cancer; clinical recommendations; guidelines; hepatitis c virus; hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

Dr Hamdy Azim reports grants, personal fees from Roche, grants from Astra Zenca, personal fees from Bayer, during the conduct of the study; grants, personal fees from Novartis, grants, personal fees from Pfizer, grants, personal fees from MSD, personal fees from BMS, personal fees from GSK, outside the submitted work. Prof. Dr. Imam Waked reports personal fees, Investigator Advisory Board Member from Astra Zeneca, personal fees from Hoffman La Roche, personal fees from Bayer, during the conduct of the study; Investigator from Abbvie, personal fees, Advisory Board from Eva Pharma, Investigator from Pfizer, other from Investigator, outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. Waked I, Esmat G, Elsharkawy A, et al. Screening and treatment program to eliminate hepatitis C in Egypt. N Eng J Med. 2020;382(12):1166–1174. doi:10.1056/NEJMsr1912628 - DOI - PubMed
    1. Laube R, Sabih A, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma. J Gastroenterol Hepatol. 2021;36(3):618–628. doi:10.1111/jgh.15169 - DOI - PubMed
    1. World Health Organization (WHO). Global Health Estimates 2020: estimated number of deaths in 2020, Egypt, both sexes, all ages (excl. NMSC). WHO; 2020. Available from: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_.... Accessed April 9, 2022.
    1. Liu Z, Jiang Y, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70(4):674–683. doi:10.1016/j.jhep.2018.12.001 - DOI - PubMed
    1. El-Zanaty F, Way A. Egypt Demographic and Health Survey, 2008 Cairo, Egypt: Ministry of Health and Population, 2009. Demographic and Health Survey (EDHS); 2009.